BONELLI, Mara
 Distribuzione geografica
Continente #
EU - Europa 240
AS - Asia 98
NA - Nord America 87
AF - Africa 5
OC - Oceania 4
SA - Sud America 2
Totale 436
Nazione #
IT - Italia 113
US - Stati Uniti d'America 81
IE - Irlanda 52
DE - Germania 26
CN - Cina 24
IN - India 14
KR - Corea 14
JP - Giappone 13
GB - Regno Unito 10
TW - Taiwan 9
VN - Vietnam 6
CA - Canada 5
FR - Francia 5
MY - Malesia 5
NL - Olanda 5
AU - Australia 4
FI - Finlandia 4
RU - Federazione Russa 4
SE - Svezia 4
BE - Belgio 3
EG - Egitto 3
UA - Ucraina 3
CH - Svizzera 2
DZ - Algeria 2
ES - Italia 2
HU - Ungheria 2
ID - Indonesia 2
KZ - Kazakistan 2
SG - Singapore 2
TH - Thailandia 2
TR - Turchia 2
BO - Bolivia 1
BR - Brasile 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
HK - Hong Kong 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
Totale 436
Città #
Dublin 51
Parma 38
Arezzo 16
Ann Arbor 12
Hangzhou 9
Medolla 8
Yongsan 7
Mcallen 6
Suita 6
Casarano 5
Naples 5
Bremen 4
Dong Ket 4
Guangzhou 4
Helsinki 4
Indianapolis 4
Rome 4
Xian 4
Beijing 3
Brooklyn 3
Council Bluffs 3
Fleming Island 3
Footscray 3
Gent 3
Leonia 3
London 3
Milan 3
Paris 3
Shanghai 3
Taipei 3
Washington 3
Waterville 3
Amstelveen 2
Ashburn 2
Bangalore 2
Boardman 2
Casina 2
Concord 2
Gladbeck 2
Gold 2
Hyderabad 2
Jijelli 2
Los Angeles 2
Madrid 2
Pittsburgh 2
Sant'ilario D'enza 2
Seoul 2
Serra 2
Slough 2
Szeged 2
Tokyo 2
Toronto 2
Vadodara 2
Weston-super-mare 2
Aktobe 1
Amagasaki 1
Ancona 1
Bacoli 1
Baltimore 1
Bengaluru 1
Bhavnagar 1
Bologna 1
Borås 1
Boston 1
Bromma 1
Cagliari 1
Caledon 1
Casalgrande 1
Chandigarh 1
Chengdu 1
Cincinnati 1
Cochabamba 1
Dallas 1
East Syracuse 1
Edmonton 1
Ferrara 1
Frederick 1
Gainesville 1
Garching 1
Genoa 1
Genova 1
Hanoi 1
Harada 1
Houston 1
Islamabad 1
Izmir 1
Kansas City 1
Konstanz 1
Kyoto 1
Lake Forest 1
Lexington 1
Memphis 1
Menlo Park 1
Milpitas 1
Modena 1
Montale 1
Monterrey 1
Moscow 1
New York 1
Norwalk 1
Totale 323
Nome #
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer, file e177fbc4-42b8-50b0-e053-d805fe0adaee 120
New therapeutic strategies for malignant pleural mesothelioma, file e177fbc7-6d9a-50b0-e053-d805fe0adaee 32
null, file e177fbc4-3a65-50b0-e053-d805fe0adaee 27
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer, file e177fbc4-374a-50b0-e053-d805fe0adaee 26
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer, file e177fbc6-c828-50b0-e053-d805fe0adaee 22
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines, file e177fbc5-e007-50b0-e053-d805fe0adaee 17
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib, file e177fbc7-275c-50b0-e053-d805fe0adaee 16
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines, file e177fbc4-3e0a-50b0-e053-d805fe0adaee 14
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells., file e177fbc5-d274-50b0-e053-d805fe0adaee 14
Heat-induced proteasomic degradation of HSF1 in serum-starved human fibroblasts aging in vitro, file e177fbc4-2222-50b0-e053-d805fe0adaee 11
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC, file e177fbc6-8be1-50b0-e053-d805fe0adaee 11
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion, file e177fbc7-5975-50b0-e053-d805fe0adaee 11
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro, file e177fbc4-0cb5-50b0-e053-d805fe0adaee 10
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity, file e177fbc4-0d42-50b0-e053-d805fe0adaee 10
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells, file e177fbc6-9bb6-50b0-e053-d805fe0adaee 9
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines, file e177fbc5-2589-50b0-e053-d805fe0adaee 8
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines., file e177fbc6-8938-50b0-e053-d805fe0adaee 8
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation, file e177fbc7-5aef-50b0-e053-d805fe0adaee 8
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway, file e177fbc7-a9df-50b0-e053-d805fe0adaee 7
New therapeutic strategies for malignant pleural mesothelioma, file e177fbc5-6e69-50b0-e053-d805fe0adaee 6
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells, file e177fbc7-4245-50b0-e053-d805fe0adaee 6
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation, file e177fbc7-1d2f-50b0-e053-d805fe0adaee 5
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation, file e177fbc7-5af1-50b0-e053-d805fe0adaee 5
Stabilization of hsp70 mRNA on prolonged cell exposure to hypertonicity, file e177fbc4-0d41-50b0-e053-d805fe0adaee 4
Synergistic activity of letrozole and sorafenib on breast cancer cells, file e177fbc4-1f38-50b0-e053-d805fe0adaee 4
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors), file e177fbc4-2810-50b0-e053-d805fe0adaee 4
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis, file e177fbc4-0cec-50b0-e053-d805fe0adaee 3
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung, file e177fbc4-8054-50b0-e053-d805fe0adaee 3
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines, file e177fbc4-1f39-50b0-e053-d805fe0adaee 2
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN, file e177fbc5-953c-50b0-e053-d805fe0adaee 2
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells, file e177fbc6-03ea-50b0-e053-d805fe0adaee 2
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation, file e177fbc7-56f9-50b0-e053-d805fe0adaee 2
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells, file e177fbc7-a024-50b0-e053-d805fe0adaee 2
The effect of heat shock on amino acid transport and cell volume in 3T3 cells, file e177fbc4-0d43-50b0-e053-d805fe0adaee 1
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity, file e177fbc4-0d44-50b0-e053-d805fe0adaee 1
Increased level of inducible HSP70 in cells exposed to electromagnetic fields., file e177fbc4-0e60-50b0-e053-d805fe0adaee 1
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification, file e177fbc4-3c48-50b0-e053-d805fe0adaee 1
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations., file e177fbc4-8faf-50b0-e053-d805fe0adaee 1
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR, file e177fbc7-ab25-50b0-e053-d805fe0adaee 1
Totale 437
Categoria #
all - tutte 715
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 715


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20182 0000 00 00 1100
2019/20201 0100 00 00 0000
2020/202116 0000 01 01 3029
2021/202258 21906 30 121 3228
2022/2023135 8125 104 1012 83000
Totale 437